Ozmosi | Metronidazole Drug Profile

Product Description

Metronidazole is one of the mainstay drugs for the treatment of anaerobic bacterial infections, protozoal infections, and microaerophilic bacterial infections. It is cytotoxic to facultative anaerobic microorganism. Metronidazole diffuses into the organism, inhibits protein synthesis by interacting with DNA and causing a loss of helical DNA structure and strand breakage. Therefore, it causes cell death in susceptible organisms. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK539728/)

Mechanisms of Action: Nucleic Acid Synthesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Intravenous

FDA Designation: *

Approval Status: Approved

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Metronidazole

Countries in Clinic: Australia, China, Denmark, France, Romania, Spain, United States

Active Clinical Trial Count: 12

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Diverticulitis|Pouchitis

Phase 1: Atrial Fibrillation|Healthy Volunteers

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
2024-517764-38-00	P2	Not yet recruiting	Pouchitis	2027-08-02		2025-05-02	Treatments
NNMAIS 01/2021	P3	Temporary halt	Vaginosis, Bacterial\|Candidiasis, Vulvovaginal	2026-07-01		2025-05-02	Treatments
DIREBIOT	P2	Recruiting	Diverticulitis	2025-12-31		2025-05-02	Treatments
ABCESS2	P3	Not yet recruiting	Hidradenitis Suppurativa	2025-12-15	26%	2024-01-14	Primary Completion Date\|Primary Endpoints\|Start Date\|Study Completion Date\|Treatments
CTR20240497	P2	Completed	Vaginosis, Bacterial	2024-12-25		2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
2017-002742-68	P3	Completed	Pneumonia, Ventilator-Associated	2023-02-23	41%	2025-06-09	Treatments
FRENCH24 ANIS	P3	Active, not recruiting	Unknown	2025-04-03
W-5222-106	P1	Recruiting	Healthy Volunteers	2025-03-01	23%	2025-02-05	Primary Endpoints\|Treatments
2006-7041-83/hah	P1	Not yet recruiting	Atrial Fibrillation	None
CTR20131052	P3	Recruiting	Vaginitis\|Vaginal Discharge	None		2025-04-29	Patient Enrollment\|Treatments
ACTRN12625000283471	P1	Not yet recruiting	Vaginosis, Bacterial	None		2025-06-02	Treatments
CTR20240668	P2	Recruiting	Vaginosis, Bacterial	None		2025-04-29

Recent News Events

Date	Type	Title
05/30/2025	News Article	Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.
05/20/2025	News Article	Saptalis Pharmaceuticals Announces the Launch of LIKMEZ® — The First and Only US FDA-Approved Ready-to-Use Oral Suspension of Metronidazole
05/19/2025	News Article	Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.
04/03/2025	News Article	Lumen Bioscience's LMN-201 Achieves 100% Initial C. difficile Clinical Cure in Preliminary Cohort of RePreve Trial

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Metronidazole